ConductScience.org, home

Library / Trials

Ocular Changes in Patients Using Tirzepatide or Semaglutide

NCT07924618, Recruiting, Istanbul University

Trial 9

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleOcular Changes in Patients Using Tirzepatide or SemaglutideClinicalTrials.gov
NCT numberNCT07924618ClinicalTrials.gov
StatusRecruitingClinicalTrials.gov
Enrollment40 participants, estimatedClinicalTrials.gov
Lead sponsorIstanbul UniversityClinicalTrials.gov
ConditionsType 2 Diabetes Mellitus, ObesityClinicalTrials.gov
InterventionsSemaglutide, TirzepatideClinicalTrials.gov
First posted2026-11-09ClinicalTrials.gov
Last updated2026-11-09ClinicalTrials.gov

Registered outcomes 8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryChange in Retinal Nerve Fiber Layer ThicknessBaseline to up to 18 monthsChange in retinal nerve fiber layer thickness from baseline during follow-up, assessed using optical coherence tomography (OCT).ClinicalTrials.gov
PrimaryChange in Retinal ThicknessBaseline to up to 18 monthsChange in retinal thickness from baseline during follow-up, assessed using optical coherence tomography (OCT).ClinicalTrials.gov
PrimaryChange in Superficial Retinal Vessel DensityBaseline to 18 monthsChange in superficial retinal capillary vessel density from baseline to follow-up, assessed using optical coherence tomography angiography (OCT-A) and expressed as a percentage (%).ClinicalTrials.gov
PrimaryChange in Deep Retinal Vessel DensityBaseline to 18 monthsChange in deep retinal capillary vessel density from baseline to follow-up, assessed using optical coherence tomography angiography (OCT-A) and expressed as a percentage (%).ClinicalTrials.gov
PrimaryChange in Foveal Avascular Zone AreaBaseline to 18 monthsChange in foveal avascular zone (FAZ) area from baseline to follow-up, measured using optical coherence tomography angiography (OCT-A) and expressed in square millimeters (mm²).ClinicalTrials.gov
PrimaryChange in Choriocapillaris Flow Deficit PercentageBaseline to 18 monthsChange in choriocapillaris flow deficit percentage from baseline to follow-up, assessed using optical coherence tomography angiography (OCT-A) and expressed as a percentage (%).ClinicalTrials.gov
SecondaryChange in Visual AcuityBaseline to up to 18 monthsChange in visual acuity from baseline during follow-upClinicalTrials.gov
SecondaryChange in Intraocular PressureBaseline to up to 18 monthsChange in intraocular pressure from baseline during follow-up, measured in mmHg during routine ophthalmologic examination.ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)